The most flexible growth model type in irregular and mixed stands is a set of individual tree models, consisting of separate models for different species or species groups, or using indicator variables for species-specific growth patterns.
Based on this model, different host species show different reservoir capacities and vary in their level of infestation by the vector such that the presence of certain host species in the community limits the transmission potential of the pathogen and thus lowers disease risk.
Despite these problems, Pukkala et al. ([2011]) were able to develop ingrowth models for different species, as well as individual-tree models for diameter increment and survival.
However, there may be some other models for different species groups by using different proportion functions.
Additionally, different cell models from different species were used in the various studies, namely mouse Raw264.7 cells, mouse BMDMs and peritoneal macrophages, rat primary alveolar macrophages or human PBMC-derived macrophages.
Such differences could be due to regional climate and vegetation differences but were also likely due to use of different global climate models, slightly different species parameters, unique fire regime scenarios, and alternative methods for calculating species establishment probabilities.
However, the paucity of below-ground tree root data globally still limits our ability to develop and refine predictive models for different species and to refine or enhance recommendations on tree density and pattern to achieve erosion control.
Finally, the paucity of below-ground tree-root data globally still limits the ability of practitioners to develop and refine predictive models for different species and/or clones and to refine or enhance recommendations on tree density and pattern to achieve erosion control.
Pre-clinical studies show that beneficial effects of adult OB-OEG are repeatable in the same type of spinal cord injury initially tested, in other spinal cord and CNS injury models, in different species and after the administration of these cells in different forms (either alone or in combination with other cells, drugs, products or devices).
